Cordis EXOSEAL Vascular Closure Device receives approval in the U.S.

Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, today announced the approval of the EXOSEAL™ Vascular Closure Device in the US. EXOSEAL™ incorporates a number of new advances in technology and simplicity of design to provide precise and secure extravascular arterial closure.

"We are very pleased to announce the approval of our first Vascular Closure Device in the United States" said Campbell Rogers, M.D., Chief Scientific Officer and Global Head, Research and Development, Cordis Corporation. "EXOSEAL™ has demonstrated excellent clinical efficacy and safety but also incorporates key design advancements intended to promote safety, ease of use and patient comfort. We are looking forward to building upon the outstanding experience that clinicians and patients have had outside the US since June 2010 when EXOSEAL™ received CE mark in Europe."

SOURCE Cordis Corporation